Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.61 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9912422 | 0.81 | BCHE (0.63) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| SCHEMBL10254172 | 0.79 | BCHE (0.72) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| SCHEMBL9477024 | 0.79 | BCHE (0.61) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| SCHEMBL334233 | 0.79 | BCHE (0.61) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| SCHEMBL8286810 | 0.79 | BCHE (0.61) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| SCHEMBL2133754 | 0.79 | BCHE (0.61) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| SCHEMBL1046146 | 0.78 | EPHX2 (0.61) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| Hydrochloric Acid SCHEMBL21296615 | 0.78 | BCHE (0.59) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| Lithium Ion SCHEMBL306751 | 0.78 | BCHE (0.59) | BCHEMDM2HDAC3HDAC4HDAC1 | |
| SCHEMBL13824324 | 0.78 | BCHE (0.59) | BCHEMDM2HDAC3HDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063221-B2 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-11-22 | — | — | US | claimed |
| EP-2013182-A2 | AMINOQUINOLONES AS GSK-3 INHIBITORS | Activx Biosciences, Inc. (US) | 2009-01-14 | — | — | EP | claimed |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | claimed |
| WO-2007106537-A2 | AMINOQUINOLONES AS GSK-3 INHIBITORS | ACTIVX BIOSCIENCES, INC. (US) | 2007-09-20 | — | — | WO | claimed |
| US-6369247-B1 | OXIDATION WITH HYDROPEROXIDE IN THE PRESENCE OF RUTHENIUM CATALYST | MERCK & CO., INC. | 2002-04-09 | — | — | US | claimed |
| EP-0759929-B1 | OXIDATION OF STEROIDS HAVING ALLYLIC GROUPS | MERCK & CO INC (US) | 2000-08-23 | — | — | EP | claimed |
| EP-0858455-A4 | 4-OXA AND 4-THIA STEROIDS | MERCK & CO INC (US) | 2000-04-12 | — | — | EP | claimed |
| US-5998464-A | 4-Oxa and 4-thia steroids | MERCK & CO., INC. (US) | 1999-12-07 | — | — | US | claimed |
| US-5817802-A | IN IONIZING MEDIUM WITH A TRIALKYLSILANE | MERCK & CO., INC. (US) | 1998-10-06 | — | — | US | claimed |
| EP-0759929-A4 | OXIDATION OF STEROIDS HAVING ALLYLIC GROUPS | MERCK & CO INC (US) | 1998-09-30 | — | — | EP | claimed |
| EP-0858455-A1 | 4-OXA AND 4-THIA STEROIDS | Merck & Co., Inc. (US) | 1998-08-19 | — | — | EP | claimed |
| WO-1997015564-A1 | 4-OXA AND 4-THIA STEROIDS | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | claimed |
| EP-0759929-A1 | OXIDATION OF STEROIDS HAVING ALLYLIC GROUPS | Merck & Co., Inc. (a New Jersey corp.) (US) | 1997-03-05 | — | — | EP | claimed |
| WO-1996007643-A1 | PROCESS FOR THE STEREOSELECTIVE REDUCTION OF STEROID ENELACTAMS | MERCK & CO., INC. (US) | 1996-03-14 | — | — | WO | claimed |
| WO-1995032215-A1 | OXIDATION OF STEROIDS HAVING ALLYLIC GROUPS | MERCK & CO., INC. (US) | 1995-11-30 | — | — | WO | claimed |
| EP-2013182-B1 | AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2383271-B1 | Aminoquinolones as GSK-3 Inhibitors | KYORIN SEIYAKU KK (JP) | 2013-07-10 | — | — | EP | disclosed |
| EP-0759929-A1 | OXIDATION OF STEROIDS HAVING ALLYLIC GROUPS | Merck & Co., Inc. (a New Jersey corp.) (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1996007643-A1 | PROCESS FOR THE STEREOSELECTIVE REDUCTION OF STEROID ENELACTAMS | MERCK & CO., INC. (US) | 1996-03-14 | — | — | WO | disclosed |
| WO-1995032215-A1 | OXIDATION OF STEROIDS HAVING ALLYLIC GROUPS | MERCK & CO., INC. (US) | 1995-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | BCHE 1537/4885MDM2 234/4885HDAC3 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.